SWTX Quote, Financials, Valuation and Earnings

Atara Biotherapeutics has a net margin of -108.58% compared to SpringWorks Therapeutics's net margin of -54.51%. SpringWorks Therapeutics's return on equity of -51.38% beat Atara Biotherapeutics's return on equity of -2818.48%.

SpringWorks Therapeutics has a consensus price target of $67.50, signalling upside risk potential of 107.69%. On the other hand Atara Biotherapeutics has an analysts' consensus of -- which suggests that it could grow by 34.04%. Given that SpringWorks Therapeutics has higher upside potential than Atara Biotherapeutics, analysts believe SpringWorks Therapeutics is more attractive than Atara Biotherapeutics.

SpringWorks Therapeutics has a beta of 0.821, which suggesting that the stock is 17.943% less volatile than S&P 500. In comparison Atara Biotherapeutics has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.464%.

SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Atara Biotherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Atara Biotherapeutics pays out -- of its earnings as a dividend.

SpringWorks Therapeutics quarterly revenues are $49.3M, which are larger than Atara Biotherapeutics quarterly revenues of $40.2M. SpringWorks Therapeutics's net income of -$53.5M is lower than Atara Biotherapeutics's net income of -$21.9M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Atara Biotherapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 17.24x versus 0.72x for Atara Biotherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Blueprint Medicines has a net margin of -108.58% compared to SpringWorks Therapeutics's net margin of -43.9%. SpringWorks Therapeutics's return on equity of -51.38% beat Blueprint Medicines's return on equity of -50.13%.

SpringWorks Therapeutics has a consensus price target of $67.50, signalling upside risk potential of 107.69%. On the other hand Blueprint Medicines has an analysts' consensus of $125.47 which suggests that it could grow by 22.34%. Given that SpringWorks Therapeutics has higher upside potential than Blueprint Medicines, analysts believe SpringWorks Therapeutics is more attractive than Blueprint Medicines.

SpringWorks Therapeutics has a beta of 0.821, which suggesting that the stock is 17.943% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.610, suggesting its less volatile than the S&P 500 by 39.048%.

SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.

SpringWorks Therapeutics quarterly revenues are $49.3M, which are smaller than Blueprint Medicines quarterly revenues of $128.2M. SpringWorks Therapeutics's net income of -$53.5M is higher than Blueprint Medicines's net income of -$56.3M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 17.24x versus 14.81x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics has a net margin of -108.58% compared to SpringWorks Therapeutics's net margin of -54.2%. SpringWorks Therapeutics's return on equity of -51.38% beat PTC Therapeutics's return on equity of --.

SpringWorks Therapeutics has a consensus price target of $67.50, signalling upside risk potential of 107.69%. On the other hand PTC Therapeutics has an analysts' consensus of $58.36 which suggests that it could grow by 39.58%. Given that SpringWorks Therapeutics has higher upside potential than PTC Therapeutics, analysts believe SpringWorks Therapeutics is more attractive than PTC Therapeutics.

SpringWorks Therapeutics has a beta of 0.821, which suggesting that the stock is 17.943% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.619, suggesting its less volatile than the S&P 500 by 38.129%.

SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

SpringWorks Therapeutics quarterly revenues are $49.3M, which are smaller than PTC Therapeutics quarterly revenues of $196.8M. SpringWorks Therapeutics's net income of -$53.5M is higher than PTC Therapeutics's net income of -$106.7M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 17.24x versus 3.55x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -108.58% compared to SpringWorks Therapeutics's net margin of 37.71%. SpringWorks Therapeutics's return on equity of -51.38% beat Vertex Pharmaceuticals's return on equity of -2.89%.

SpringWorks Therapeutics has a consensus price target of $67.50, signalling upside risk potential of 107.69%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $489.81 which suggests that it could grow by 18.98%. Given that SpringWorks Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe SpringWorks Therapeutics is more attractive than Vertex Pharmaceuticals.

SpringWorks Therapeutics has a beta of 0.821, which suggesting that the stock is 17.943% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.399, suggesting its less volatile than the S&P 500 by 60.102%.

SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

SpringWorks Therapeutics quarterly revenues are $49.3M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. SpringWorks Therapeutics's net income of -$53.5M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 17.24x versus 10.08x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.